PPARγ2 Pro12Ala Polymorphism and Insulin Resistance in Japanese Hypertensive Patients

Junko YAMAMOTO; Shigeru KAGEYAMA; Masami NEMOTO; Takashi SASAKI; Tatsuya SAKURAI; Ken-ichi ISHIBASHI; Akira MIMURA; Kuninobu YOKOTA; Naoko TAJIMA

doi:10.1291/hypres.25.25

Clinical studies

PPARγ2 Pro12Ala Polymorphism and Insulin Resistance in Japanese Hypertensive Patients

Junko YAMAMOTO, Shigeru KAGEYAMA, Masami NEMOTO, Takashi SASAKI, Tatsuya SAKURAI, Ken-ichi ISHIBASHI, Akira MIMURA, Kuninobu YOKOTA, Naoko TAJIMA

Author information

Junko YAMAMOTO
Division of Clinical Pharmacology and Therapeutics, Jikei University School of Medicine
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine
Shigeru KAGEYAMA
Division of Clinical Pharmacology and Therapeutics, Jikei University School of Medicine
Masami NEMOTO
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine
Takashi SASAKI
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine
Tatsuya SAKURAI
Division of Clinical Pharmacology and Therapeutics, Jikei University School of Medicine
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine
Ken-ichi ISHIBASHI
Division of Clinical Pharmacology and Therapeutics, Jikei University School of Medicine
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine
Akira MIMURA
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine
Kuninobu YOKOTA
Division of Clinical Pharmacology and Therapeutics, Jikei University School of Medicine
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine
Naoko TAJIMA
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine

Keywords: peroxisome proliferator-activated receptor γ (PPARγ), insulin resistance, hypertension, glucose clamp, β₃ adrenergic receptor

JOURNAL FREE ACCESS

2002 Volume 25 Issue 1 Pages 25-29

DOI https://doi.org/10.1291/hypres.25.25

Details

Abstract

We investigated the relationship between peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala substitution and insulin resistance in subjects with normal insulin secretory capacity, since it has been reported that PPARγ may affect not only insulin resistance but also insulin secretion. We examined 81 Japanese male patients with untreated essential hypertension using the glucose clamp technique. We found 77 subjects with Pro⁄Pro and 4 subjects with Pro⁄Ala genotype, and the glucose disposal rate was not significantly different between the two groups. Fasting plasma glucose, fasting immunoreactive insulin, total cholesterol, HDL cholesterol, and triglyceride were not significantly different between the two groups. There were also no significant differences between groups in homeostasis model assessment of insulin resistance (HOMA-R) values, area under the curve (AUC) for plasma glucose, or AUC for IRI in 75 g OGTT. Because insulin sensitivity is likely to be determined by polygenic factors, we also investigated β₃ adrenergic receptor Trp64Arg polymorphism as a possible determinant of insulin resistance. In conclusion, no significant association was observed between PPARγ2 substitution and insulin sensitivity in the present cohort of Japanese hypertensive patients. (Hypertens Res 2002; 25: 25-29)

Corresponding author

Register with J-STAGE for free!